{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:43:24Z","timestamp":1786977804530,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl J Gynecology &amp; Obste"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the effects of 52\u2009weeks of treatment with relugolix combination therapy (relugolix 40\u2009mg, estradiol 1\u2009mg, norethindrone acetate 0.5\u2009mg) on symptoms of uterine fibroids (UF) and quality of life (QoL) in women with heavy menstrual bleeding associated with UF and anemia (hemoglobin \u226410.5\u2009g\/dL) at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis included women from the LIBERTY long\u2010term extension study with anemia (hemoglobin concentration \u226410.5\u2009g\/dL) at pivotal study baseline and documented hemoglobin values at week 52 (anemia\u2010evaluable population). Treatment responders: women achieving a menstrual blood loss volume of &lt;80\u2009mL and a \u226550% reduction over the last 35\u2009days of treatment. Anemia responders were women achieving a hemoglobin increase of &gt;2\u2009g\/dL from baseline to week 52. Least squares (LS) mean changes from baseline in uterine fibroid symptom (UFS)\u2010QoL symptom severity, fatigue, and health\u2010related QoL total (HR\u2010QoL) and (sub)scale scores were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 115 women were included in the anemia\u2010evaluable population. Of 39 anemia\u2010evaluable women who received continuous treatment with relugolix combination therapy for 52\u2009weeks, 34 (87.2%) met treatment responder criteria and 23 (59.0%) were anemia responders. LS mean hemoglobin concentration increased by 29.4% at week 52. LS mean UFS\u2010QoL symptom severity and fatigue scores decreased by 38.5 and 31.9 points, respectively, and HR\u2010QoL total score increased by 41.6 points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In women with UF and a high disease burden due to anemia, relugolix combination therapy substantially improved hemoglobin levels, decreased distress due to symptoms, especially fatigue, over 52\u2009weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ijgo.15505","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T01:54:31Z","timestamp":1712282071000},"page":"431-441","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quality of life improvements in women with uterine fibroids treated with relugolix combination therapy during the\n                    <scp>LIBERTY<\/scp>\n                    long\u2010term extension study: A descriptive subgroup analysis in women with anemia at baseline"],"prefix":"10.1002","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1359-770X","authenticated-orcid":false,"given":"Roberta","family":"Venturella","sequence":"first","affiliation":[{"name":"Department of Experimental and Clinical Medicine Magna Gr\u00e6cia University of Catanzaro  Catanzaro Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea S.","family":"Lukes","sequence":"additional","affiliation":[{"name":"Carolina Women's Research and Wellness Center  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wu","sequence":"additional","affiliation":[{"name":"Data Science Sumitomo Pharma America, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"McLean","sequence":"additional","affiliation":[{"name":"Clinical Research Sumitomo Pharma America, Inc.  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viatcheslav G.","family":"Rakov","sequence":"additional","affiliation":[{"name":"Medical Affairs Sumitomo Pharma Switzerland GmbH  Basel Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Al\u2010Hendy","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology University of Chicago  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1152\/physiol.00013.2021"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0000000000000171"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40834-017-0047-4"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.35.2.644"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11605"},{"issue":"10","key":"e_1_2_12_7_1","first-page":"799","article-title":"The impact of anemia on treatment management and clinical outcomes of women hospitalized for uterine leiomyomas","volume":"93","author":"Antunes D","year":"2022","journal-title":"Ginekol Pol"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.12394"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.633180"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2014.12.016"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2019.07.013"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008283"},{"key":"e_1_2_12_13_1","unstructured":"European Medicines Agency.Ryeqo (40\u2009mg relugolix 1\u2009mg estradiol (as hemihydrate) and 0.5\u2009mg norethisterone acetate) Summary of product characteristics.2024. Accessed March 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ryeqo\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_12_14_1","unstructured":"US Food and Drug Administration.Myfembree (relugolix estradiol northindrone acetate) prescribing information.2021. Accessed August 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214846s000lbl.pdf"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004988"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2022.11.1278"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200202000-00021"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c332"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-019-0146-x"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3310\/ZDEG6110"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2012.07.005"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(15)30338-8"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000547"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V19.3.2022311"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000140"}],"container-title":["International Journal of Gynecology &amp; Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijgo.15505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:26:15Z","timestamp":1721175975000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1002\/ijgo.15505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1002\/ijgo.15505"],"URL":"https:\/\/doi.org\/10.1002\/ijgo.15505","archive":["Portico"],"relation":{},"ISSN":["0020-7292","1879-3479"],"issn-type":[{"value":"0020-7292","type":"print"},{"value":"1879-3479","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"2023-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}